GenMont Biotech, Inc.(TW:3164)
NT$16.750.00 (0.00%)
TW:3164
GenMont Biotech, Inc. financials statements
NT$16.75
At close:0.00 (0.00%)
GenMont Biotech, Inc. (3164) Ratios
GenMont Biotech, Inc. Ratios
TW:3164's free cash flow for Q2 2026 was NT$26.01M. For the 2026 fiscal year, TW:3164's free cash flow was decreased by NT$-414.00K and operating cash flow was NT$26.43M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.28 | 3.87 | 3.18 | 3.24 | 4.17 |
| Quick Ratio | 3.74 | 3.31 | 2.58 | 2.90 | 3.91 |
| Cash Ratio | 0.80 | 0.79 | 0.38 | 0.83 | 1.22 |
| Solvency Ratio | 0.58 | 0.56 | 0.48 | 0.54 | 0.77 |
| Operating Cash Flow Ratio | 0.57 | 0.88 | 0.24 | 0.85 | 0.80 |
| Short-Term Operating Cash Flow Coverage | 2.39 | 3.79 | 15.48 | 0.00 | 0.00 |
| Net Current Asset Value | NT$ 339.96M | NT$ 312.67M | NT$ 261.45M | NT$ 322.91M | NT$ 407.14M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.07 | 0.07 | 0.04 | 0.02 | 0.02 |
| Debt-to-Equity Ratio | 0.08 | 0.09 | 0.04 | 0.03 | 0.02 |
| Debt-to-Capital Ratio | 0.08 | 0.08 | 0.04 | 0.02 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.03 | 0.04 | 0.02 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.25 | 1.26 | 1.26 | 1.25 | 1.23 |
| Debt Service Coverage Ratio | 3.14 | 3.38 | 27.49 | 130.64 | 171.63 |
| Interest Coverage Ratio | 14.75 | 10.79 | 7.18 | 79.71 | 187.32 |
| Debt to Market Cap | 0.06 | 0.05 | 0.01 | 0.00 | 0.00 |
| Interest Debt Per Share | 1.57 | 1.41 | 0.68 | 0.41 | 0.39 |
| Net Debt to EBITDA | 0.05 | 0.06 | 0.03 | -0.84 | -0.85 |
| Profitability Margins | |||||
| Gross Profit Margin | 62.72% | 61.80% | 66.41% | 69.66% | 69.95% |
| EBIT Margin | 14.39% | 17.76% | 9.16% | 18.18% | 32.76% |
| EBITDA Margin | 31.05% | 36.34% | 29.53% | 31.86% | 37.69% |
| Operating Profit Margin | 14.39% | 10.41% | 2.20% | 16.33% | 33.53% |
| Pretax Profit Margin | 15.87% | 16.79% | 8.86% | 17.98% | 32.58% |
| Net Profit Margin | 14.26% | 14.86% | 10.37% | 15.46% | 26.44% |
| Continuous Operations Profit Margin | 11.96% | 12.39% | 7.05% | 12.88% | 25.61% |
| Net Income Per EBT | 89.82% | 88.46% | 117.14% | 85.99% | 81.14% |
| EBT Per EBIT | 110.27% | 161.32% | 403.02% | 110.10% | 97.17% |
| Return on Assets (ROA) | 3.44% | 3.35% | 2.00% | 3.36% | 6.66% |
| Return on Equity (ROE) | 4.30% | 4.24% | 2.51% | 4.22% | 8.22% |
| Return on Capital Employed (ROCE) | 3.76% | 2.56% | 0.46% | 3.92% | 9.20% |
| Return on Invested Capital (ROIC) | 2.78% | 1.85% | 0.37% | 2.81% | 7.23% |
| Return on Tangible Assets | 3.44% | 3.35% | 2.00% | 3.36% | 6.66% |
| Earnings Yield | 4.29% | 3.28% | 1.54% | 2.78% | 5.38% |
| Efficiency Ratios | |||||
| Receivables Turnover | 8.56 | 11.56 | 7.95 | 7.12 | 7.77 |
| Payables Turnover | 18.38 | 23.35 | 13.60 | 7.78 | 11.29 |
| Inventory Turnover | 2.13 | 1.90 | 1.21 | 2.02 | 3.47 |
| Fixed Asset Turnover | 0.41 | 0.37 | 0.30 | 0.33 | 0.40 |
| Asset Turnover | 0.24 | 0.23 | 0.19 | 0.22 | 0.25 |
| Working Capital Turnover Ratio | 0.97 | 1.07 | 0.94 | 0.92 | 0.91 |
| Cash Conversion Cycle | 194.53 | 208.53 | 320.19 | 184.89 | 119.83 |
| Days of Sales Outstanding | 42.66 | 31.57 | 45.93 | 51.26 | 46.96 |
| Days of Inventory Outstanding | 171.74 | 192.59 | 301.09 | 180.51 | 105.19 |
| Days of Payables Outstanding | 19.86 | 15.63 | 26.83 | 46.89 | 32.33 |
| Operating Cycle | 214.40 | 224.16 | 347.02 | 231.77 | 152.16 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.01 | 1.43 | 0.40 | 1.59 | 1.29 |
| Free Cash Flow Per Share | 0.96 | 0.92 | -0.01 | 0.76 | -0.06 |
| Dividend Paid and CapEx Coverage Ratio | 1.01 | 1.42 | 0.36 | 0.83 | 0.63 |
| Capital Expenditure Coverage Ratio | 20.14 | 2.80 | 0.97 | 1.93 | 0.95 |
| Operating Cash Flow Coverage Ratio | 0.67 | 1.04 | 0.59 | 3.97 | 3.41 |
| Operating Cash Flow to Sales Ratio | 0.18 | 0.32 | 0.11 | 0.37 | 0.26 |
| Free Cash Flow Yield | 5.24% | 4.56% | -0.04% | 3.23% | -0.26% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 27.80 | 30.61 | 65.00 | 35.91 | 18.59 |
| Price-to-Sales (P/S) Ratio | 3.32 | 4.53 | 6.72 | 5.55 | 4.91 |
| Price-to-Book (P/B) Ratio | 1.00 | 1.29 | 1.62 | 1.51 | 1.53 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 19.07 | 21.93 | -2272.35 | 30.99 | -385.27 |
| Price-to-Operating Cash Flow Ratio | 18.13 | 14.10 | 61.80 | 14.94 | 18.83 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.42 | -1.53 | -0.72 | 0.21 |
| Enterprise Value Multiple | 10.76 | 12.54 | 22.80 | 16.59 | 12.19 |
| Enterprise Value | 1.34B | 1.76B | 2.14B | 1.95B | 1.97B |
| EV to EBITDA | 10.76 | 12.54 | 22.80 | 16.59 | 12.19 |
| EV to Sales | 3.34 | 4.56 | 6.73 | 5.29 | 4.59 |
| EV to Free Cash Flow | 19.17 | 22.04 | -2275.23 | 29.49 | -360.13 |
| EV to Operating Cash Flow | 18.22 | 14.16 | 61.88 | 14.22 | 17.60 |
| Tangible Book Value Per Share | 19.91 | 17.08 | 16.71 | 17.33 | 17.65 |
| Shareholders’ Equity Per Share | 18.31 | 15.63 | 15.21 | 15.65 | 15.94 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.25 | 0.26 | 0.20 | 0.28 | 0.21 |
| Revenue Per Share | 5.52 | 4.45 | 3.67 | 4.27 | 4.96 |
| Net Income Per Share | 0.79 | 0.66 | 0.38 | 0.66 | 1.31 |
| Tax Burden | 0.90 | 0.88 | 1.17 | 0.86 | 0.81 |
| Interest Burden | 1.10 | 0.95 | 0.97 | 0.99 | 0.99 |
| Research & Development to Revenue | 0.11 | 0.12 | 0.15 | 0.16 | 0.06 |
| SG&A to Revenue | 0.28 | 0.40 | 0.49 | 0.37 | 0.34 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.16 | 1.92 | 1.05 | 2.07 | 0.80 |
Currency in TWD
